Back

IASLC-WCLC-I 2020 - 2020 IASLC WCLC Presidential Symposium (Virtual Meeting)

Aug 08 - Aug 08, 2020 | SingaporeSingapore

LARVOL is not affiliated with 2020 IASLC WCLC Presidential Symposium (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners

Condition
Stage
Treatment
Setting
Biomarker
Trial Name/ID

Showing 5 abstracts linked to Trials

[VIRTUAL] ORIENT-11: Sintilimab + Pemetrexed + Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC

[VIRTUAL] Phase 3 Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK)–Positive NSCLC Patients: eXalt3

[VIRTUAL] First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

[VIRTUAL] First-line Sintilimab Plus Platinum-Based Chemotherapy Prolongs PFS in Advanced Nonsquamous NCLC

[VIRTUAL] eXalt3 Findings Support Ensartinib as a First-Line Treatment Option in ALK-positive NSCLC